CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 574 enrolled
Drug / intervention
Flovent Diskus® 100 mcg +4 moredrug
Likely dose
Flovent Diskus® 100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01967173
NCT01967173Phase 3Completed
CompareCT.gov

Best African American Response to Asthma Drugs

Milton S. Hershey Medical Center·interventional·Posted Oct 22, 2013·Updated Nov 15, 2018

In Brief

A Phase 3 clinical trial evaluating Flovent Diskus® 100 mcg, Flovent Diskus® 250 mcg, and 3 other interventions for Asthma. Completed, enrolled 574 participants across 28 sites.

Detailed Summary

The purpose of this study is to find the best asthma treatment to add for Blacks who have asthma that is not well controlled on a low dose of inhaled steroid. This study will also try to find out if Black adults and children differ in how they respond to the medications used in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 22, 2013
Enrollment StartFeb 1, 2014
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.7 years ago

Interventions

Flovent Diskus® 100 mcgdrug

Flovent is an ICS

Flovent Diskus® 250 mcgdrug

Flovent is an ICS

Flovent Diskus® 500 mcgdrug

Flovent is an ICS

Advair Diskus® 100/50 mcgdrug

Advair is an ICS/LABA combination

Advair Diskus® 250/50 mcgdrug

Advair is an ICS/LABA combination